Importantly, this functional interplay grounded the utility of A2AR blockade in PD treatment, which recently ended with the approval of a selective A2AR antagonist, istradefylline (Nourianz), as an adjuvant drug in PD treatment. This evidence concerns the gene ADORA2A and Parkinson disease.